Click here to view the interview video with one of the authors - Professor Sungha Park
Click here to view the interview video with lead investigator - Professor Kazuomi Kario
Very early invasive coronary angiography within 12 hours does not significantly improve long-term outcomes of patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) compared with the standard strategy of evaluation within 48–72 hours, according to results of the VERDICT trial reported at the European Society of Cardiology (ESC) Congress 2018.
In patients with left-sided infective endocarditis in stable condition, switching to oral antibiotics is as effective and safe as continued treatment with intravenous (IV) antibiotics, according to results of the POET trial reported at the European Society of Cardiology (ESC) Congress 2018.
Treatment with rivaroxaban for 45 days after hospital discharge reduces symptomatic venous thromboembolism (VTE), but not VTE-related mortality, in medically ill patients, results of the MARINER trial have shown.
The use of high-sensitivity cardiac troponin assays was not associated with a lower subsequent incidence of myocardial infarction (MI) or cardiovascular death at 1 year, according to results of the High-STEACS trial reported at the European Society of Cardiology (ESC) Congress 2018.
The new 2018 European Society of Cardiology (ESC)/European Society of Hypertension (ESH) guidelines for the management of arterial hypertension recommend starting treatment for most patients with a two-in-one pill containing an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) in combination with a calcium channel blocker (CCB) or diuretic.
Percutaneous mitral-valve repair with MitraClip failed to improve clinical outcomes in chronic heart failure (HF) patients with severe secondary mitral regurgitation, according to the MITRA-FR study presented at the European Society of Cardiology (ESC) Congress 2018.